| Business

Become a contributor

Bookmark Econotimes

| Business

FDA Targets Hims & Hers Over $49 Weight-Loss Pill, Raising Legal and Safety Concerns

TSMC Eyes 3nm Chip Production in Japan with $17 Billion Kumamoto Investment

Baidu Approves $5 Billion Share Buyback and Plans First-Ever Dividend in 2026

Hims & Hers Halts Compounded Semaglutide Pill After FDA Warning

Trump Backs Nexstar–Tegna Merger Amid Shifting U.S. Media Landscape

Amazon Stock Rebounds After Earnings as $200B Capex Plan Sparks AI Spending Debate

Nvidia, ByteDance, and the U.S.-China AI Chip Standoff Over H200 Exports

TrumpRx Website Launches to Offer Discounted Prescription Drugs for Cash-Paying Americans

SoftBank Shares Slide After Arm Earnings Miss Fuels Tech Stock Sell-Off

Prudential Financial Reports Higher Q4 Profit on Strong Underwriting and Investment Gains

Instagram Outage Disrupts Thousands of U.S. Users

CK Hutchison Launches Arbitration After Panama Court Revokes Canal Port Licences

Nasdaq Proposes Fast-Track Rule to Accelerate Index Inclusion for Major New Listings

Toyota’s Surprise CEO Change Signals Strategic Shift Amid Global Auto Turmoil

Once Upon a Farm Raises Nearly $198 Million in IPO, Valued at Over $724 Million

Missouri Judge Dismisses Lawsuit Challenging Starbucks’ Diversity and Inclusion Policies

Weight-Loss Drug Ads Take Over the Super Bowl as Pharma Embraces Direct-to-Consumer Marketing

©Econometrics LLC . All Rights Reserved.

Vical to Provide Company Update at BIO Asia International Conference

Thursday, March 9, 2017 12:00 PM UTC

SAN DIEGO, March 09, 2017 -- Vical Incorporated (Nasdaq:VICL) today announced that the company will provide an overview of its technologies, development programs, and outlook at 10:45 a.m. JST on Tuesday, March 14, at the Biotechnology Innovation Organization (BIO) Asia International Conference (Tokyo – March 14-15). A copy of the presentation will be available through the Events & Presentations page in the Investors section of the Vical website at www.vical.com.

About Vical
Vical develops biopharmaceutical products for the prevention and treatment of chronic or life-threatening infectious diseases, based on its patented DNA delivery technologies and other therapeutic approaches. Additional information on Vical is available at www.vical.com.

Tony Ramos
(858) 646-1127
Website: www.vical.com

Editor's Picks

Breathing through your nose when you exercise may make your runs easier

Entrepreneurs are facing a mental health crisis — here's how to help them

Are fish oil supplements as healthy as we think? And is eating fish better?

Will AI kill our creativity? It could – if we don’t start to value and protect the traits that make us human

Does AI have a right to free speech? Only if it supports our right to free thought

How can I lower my cholesterol? Do supplements work? How about psyllium or probiotics?

Why we need to set limits on sperm donation

Aging with a healthy brain: How lifestyle changes could help prevent up to 40% of dementia cases

Seven techniques to avoid weight regain, approved by experts

Market Data

Japan Election 2026: Sanae Takaichi Poised for Landslide Win Despite Record Snowfall

India–U.S. Interim Trade Pact Cuts Auto Tariffs but Leaves Tesla Out

Russian Stocks End Mixed as MOEX Index Closes Flat Amid Commodity Strength

Netanyahu to Meet Trump in Washington as Iran Nuclear Talks Intensify

US Pushes Ukraine-Russia Peace Talks Before Summer Amid Escalating Attacks

Jack Lang Resigns as Head of Arab World Institute Amid Epstein Controversy

Trump’s Inflation Claims Clash With Voters’ Cost-of-Living Reality

South Africa Eyes ECB Repo Lines as Inflation Eases and Rate Cuts Loom

Trump Backs Nexstar–Tegna Merger Amid Shifting U.S. Media Landscape

EconoTimes

Disclaimer: EconoTimes provides references and links to selected blogs and other sources of economic and market information as an educational service to its clients and prospects and does not endorse the opinions or recommendations of the blogs or other sources of information. Clients and prospects are advised to carefully consider the opinions and analysis offered in the blogs or other information sources in the context of the client or prospect's individual analysis and decision making. None of the blogs or other sources of information is to be considered as constituting a track record. Past performance is no guarantee of future results and EconoTimes specifically advises clients and prospects to carefully review all claims and representations made by advisors, bloggers, money managers and system vendors before investing any funds or opening an account with any Brokerage. Any news, opinions, research, data, or other information contained within this website is provided as general market commentary and does not constitute investment or trading advice. EconoTimes expressly disclaims any liability for any lost principal or profits without limitation which may arise directly or indirectly from the use of or reliance on such information. As with all such advisory services, past results are never a guarantee of future results.

Vical to Provide Company Update at BIO Asia International Conference

Editor's Picks

Welcome to EconoTimes